Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
RESEARCH TOOLSreports
Holding RNAC?
Track your performance easily
RNAC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.67 - $42.60
Previous Close$19.8
Volume101.31K
Average Volume (3M)95.07K
Market Cap
$456.61M
Enterprise Value$384.25M
Total Cash (Recent Filing)$87.23M
Total Debt (Recent Filing)$14.87M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Aug 08, 2024EPS Estimate
-$0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-53.26
Shares Outstanding21,382,485
10 Day Avg. Volume77,040
30 Day Avg. Volume95,073
Standard Deviation0.25
R-Squared0.02
Alpha0.00931
Financial Highlights & Ratios
Price to Book (P/B)-4.40
Price to Sales (P/S)7.83
Price to Cash Flow (P/CF)-7.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.10
Enterprise Value/Gross Profit14.78
Enterprise Value/Ebitda-1.93
Forecast
1Y Price Target
$42.00Price Target Upside101.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Cartesian Therapeutics News
PremiumCompany Announcements
Cartesian Therapeutics Reports Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressPatients treated with Descartes-08 experienced a reduction in anti-acetylcholine receptor antibody levels, while those on placebo showed an increase.
Regulatory AdvancementCartesian plans to have an End-of-Phase 2 meeting with the FDA to discuss plans for initiating a Phase 3 Trial of Descartes-08 in myasthenia gravis.
Safety And EfficacyDescartes-08 treatment did not deplete the broader antibody repertoire or decrease vaccine titers, indicating a positive safety attribute.
Bears Say
Clinical DataFailure to generate favorable clinical data from ongoing programs, particularly Descartes-08 in MG, poses a risk.
Financial PerformanceAnalyst's recommendation maintains a Buy Rating and is lowering the Target to $41 due to increased dilution.
Market ReactionRNAC trading down ~35% at the close, due to disappointments with Phase 2b Descartes-08 data in myasthenia gravis, is overdone.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RNAC FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was $11.66 and its highest was $42.60 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Currently, no data Available
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is 96 days ago.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on May 08, 2024. The company reported -$10.5 earnings per share for the quarter, missing the consensus estimate of -$0.885 by -$9.615.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate is -$0.86.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 23,893,524 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of -$10.5 in its last earnings report, missing expectations of -$0.885. Following the earnings report the stock price went down -9.43%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Among the largest hedge funds holding Cartesian Therapeutics’s share is Delphi Financial Group, Inc.. It holds Cartesian Therapeutics’s shares valued at 595K.
---
Cartesian Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.00 (101.34% Upside)
$42.00 (101.34% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 442.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-36.78%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
149.26%
Trailing 12-Months
Company Description
Cartesian Therapeutics
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
---
RNAC Earnings Call
Q2 2023
0:00 / 0:00
---
RNAC Stock 12 Month Forecast
Average Price Target
$42.00
▲(101.34% Upside)
Technical Analysis
Best Analysts Covering RNAC
1 Year
1 Year Success Rate
11/32 ratings generated profit
1 Year Average Return
-15.87%
reiterated a buy rating 3 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 34.38% of your transactions generating a profit, with an average return of -15.87% per trade.
---